Companies › Vitruvian Medical Devices
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DERMASEAL Planar thin film skin substitute containing silver microparticles | – | Phase 1 | Foot Ulcer, Diabetic | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05586542 | DERMASEAL | Phase 1 | Foot Ulcer, Diabetic | Metabolic and endocrine | Mar 2025 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.